Indrani Poddar

ORCID: 0000-0003-1485-9441
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroscience and Neuropharmacology Research
  • Pesticide Exposure and Toxicity
  • Nerve injury and regeneration
  • Neurogenesis and neuroplasticity mechanisms
  • Cancer survivorship and care
  • Environmental Toxicology and Ecotoxicology
  • Carcinogens and Genotoxicity Assessment
  • Phosphodiesterase function and regulation
  • Epilepsy research and treatment
  • Systemic Lupus Erythematosus Research
  • Otitis Media and Relapsing Polychondritis
  • Treatment of Major Depression
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Nicotinic Acetylcholine Receptors Study
  • Cancer Treatment and Pharmacology
  • Receptor Mechanisms and Signaling
  • Immunotoxicology and immune responses
  • Economic and Financial Impacts of Cancer
  • Cholinesterase and Neurodegenerative Diseases
  • Autism Spectrum Disorder Research
  • Pesticide and Herbicide Environmental Studies
  • Electroconvulsive Therapy Studies
  • Traumatic Brain Injury and Neurovascular Disturbances
  • Anesthesia and Neurotoxicity Research
  • Schizophrenia research and treatment

Augusta University
2015-2020

Kasturba Medical College, Mangalore
2015

Kasturba Medical College, Manipal
2015

Georgia Regents Medical Center
2015

Manipal Academy of Higher Education
2012

Background: Breast cancer is one of the most frequent occurring cancers in women and burgeoning worldwide. It second common malignancy India after carcinoma uterine cervix. In clinical trials, quality life (QOL) outcome measurements an important as endpoints with improving subjects physical, emotional, social well-being.Methods: this study, we were evaluated comparison QOL breast patients on anthracycline-based regimen (six cycles 5-fluorouracil, adriamycin, cyclophosphamide [FAC] for a...

10.18203/2319-2003.ijbcp20150369 article EN International Journal of Basic & Clinical Pharmacology 2015-01-01

Background: Currently, therapy for Alzheimer’s disease (AD) is only symptomatic. Only two classes of drugs are approved by the United States Food and Drug Administration. Our study aimed at comparing efficacy safety memantine donepezil in moderate to severe AD patients.Methods: Totally, 22 patients with were randomized into 2 arms study. The was divided an initial 4 weeks determination onset subsequent 28 treatment phase. Onset response defined as >20% >50% reduction mean total score...

10.5455/2319-2003.ijbcp20150415 article EN International Journal of Basic & Clinical Pharmacology 2015-01-01

Management of depression presents a significant medical challenge. Drugs with improved efficacy and better tolerability are valuable additions to the present therapy this disorder. Evidence suggests that combined serotonin noradrenaline reuptake inhibitor may be more effective major depressive disorder (MDD) than single neurotransmitter inhibitor. The study assessed between duloxetine (dual inhibitor) 40-60 mg/day escitalopram (single 10-20mg/day in 24 patients as an open labeled randomized...

10.7439/ijpr.v5i1.1589 article EN International Journal of Pharmacological Research 2015-02-13

(p1⁄40.058) between the GDS score and time to conversion dementia. Only one subject had 9 on GDS. There was also a significant separation in aMCI-MD naMCI subtypes (F1⁄44.462, p1⁄40.04).Conclusions:Early signs of behavioral changemay provide insight into risk disease progression from MCI dementia, as well aid better characterization subtypes. Further work is necessary establish whether presence sub-clinical depression or other NPS symptoms affect rate Continuing focuses imaging correlates changes its

10.1016/j.jalz.2013.08.084 article EN Alzheimer s & Dementia 2012-07-01
Coming Soon ...